articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The PI3K pathway as drug target in human cancer.

  2010cited by this paper
• Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

  2009cited by this paper
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• A genomic strategy to elucidate modules of oncogenic pathway signaling networks.

  2009cited by this paper
• The most important news at ASCO 2009

  2009cited by this paper
• Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor

  2009cited by this paper
• Biomarker Discovery: Identification of a Growth Factor Gene Signature

  2009cited by this paper
• Ras signaling and therapies.

  2009cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• High‐resolution genomic and expression analyses of copy number alterations in breast tumors

  2008cited by this paper
• Cross platform microarray analysis for robust identification of differentially expressed genes

  2007cited by this paper
• Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007influential reference
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma

  2006cited by this paper
• Genomic signatures to guide the use of chemotherapeutics

  2006cited by this paper
• Oncogenic pathway signatures in human cancers as a guide to targeted therapies

  2006cited by this paper
• A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

  2006cited by this paper
• Strategies for comparing gene expression profiles from different microarray platforms: application to a case-control experiment.

  2006cited by this paper
• An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis

  2005cited by this paper
• Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes

  2005cited by this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer

  2001cited by this paper
• Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

  2001cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper

• Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy

  2026cites this paper
• Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive Technology

  2025cites this paper
• Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer

  2025cites this paper
• Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

  2025cites this paper
• Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma

  2025cites this paper
• Cooperation between oncogenic NRF2 and wild-type HRas promotes progression of breast cancer.

  2025cites this paper
• Advanced dual primary male breast cancer and lung cancer: A case report and literature review

  2025cites this paper
• Molecular and Clinicopathological Correlates of Wild-Type KRAS Expression in Prostate Cancer

  2024cites this paper
• Oncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective

  2024cites this paper
• Exploring the Role of CBX3 as a Potential Therapeutic Target in Lung Cancer

  2024cites this paper
• Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg

  2023cites this paper
• Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

  2023cites this paper
• Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasis

  2023cites this paper
• Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia

  2022influential citation
• Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines

  2022influential citation
• An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

  2022cites this paper
• Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture

  2022influential citation
• Silencing effects of mutant RAS signalling on transcriptomes.

  2022cites this paper
• The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis

  2022cites this paper
• Hyper-active RAS/MAPK introduces cancer-specific mitotic vulnerabilities

  2022cites this paper
• RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma

  2022cites this paper
• CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax

  2022cites this paper
• Dissecting the critical pathway crosstalk mechanisms of thyroid cancer based on drug-target genes and disease genes

  2021cites this paper
• Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

  2021cites this paper
• Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

  2021cites this paper
• Genomic features of rapid versus late relapse in triple negative breast cancer

  2021cites this paper
• Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer

  2020cites this paper
• Super enhancers define regulatory subtypes and cell identity in neuroblastoma

  2020cites this paper
• Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells.

  2020cites this paper
• BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition.

  2020cites this paper
• The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness

  2020cites this paper
• Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers

  2020cites this paper
• A tyrosine kinase protein interaction map reveals targetable EGFR network oncogenesis in lung cancer

  2020cites this paper
• ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications

  2020cites this paper
• K-Ras prenylation as a potential anticancer target

  2020cites this paper
• Molecular Biomarkers of K-RAS Dependency

  2020cites this paper
• MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

  2019cites this paper
• Crosstalk between Estrogen Signaling and Breast Cancer Metabolism.

  2019cites this paper
• Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis

  2019cites this paper
• Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

  2019cites this paper
• An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.

  2019cites this paper
• Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets.

  2019cites this paper
• Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic Ductal Adenocarcinoma.

  2019cites this paper
• Using Transcriptional Signatures to Find Cancer Drivers with LURE

  2019cites this paper
• Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

  2019cites this paper
• Drug repurposing to overcome resistance to various therapies for colorectal cancer

  2019cites this paper
• Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations

  2019cites this paper
• Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.

  2018cites this paper
• A modified gene trap approach for improved high-throughput cancer drug discovery

  2018cites this paper
• Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy

  2018cites this paper
• Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors

  2018cites this paper
• Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma

  2018influential citation
• RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.

  2018cites this paper
• KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex

  2018cites this paper
• EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non-small cell lung cancer cells

  2018cites this paper
• Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells

  2018influential citation
• Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade

  2017influential citation
• Analysis of K-Ras Interactions by Biotin Ligase Tagging.

  2017cites this paper
• Conditional expression of Ki-RasG12V in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ERα)-positive adenocarcinoma

  2017cites this paper
• Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression.

  2017cites this paper
• Patient-Derived Mouse Models of Cancer

  2017cites this paper
• Maximising the potential of AKT inhibitors as anti‐cancer treatments

  2017cites this paper
• Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

  2017cites this paper
• Molecular stratification of colorectal cancer populations and its use in directing precision medicine

  2017cites this paper
• Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.

  2017cites this paper
• Molecular Characteristics of Patient-Derived Tumor Xenografts: Similarities to Patient Tumors and Relevance for Biomarker Discovery

  2017cites this paper
• Inhibition of Ciliogenesis Promotes Hedgehog Signaling, Tumorigenesis, and Metastasis in Breast Cancer

  2017cites this paper
• Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2

  2017cites this paper
• Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

  2017influential citation
• Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.

  2017cites this paper
• BCL-XL directly modulates RAS signalling to favour cancer cell stemness

  2017cites this paper
• Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

  2017cites this paper
• Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

  2016cites this paper
• An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

  2016cites this paper
• Critical parameters in targeted drug development: the pharmacological audit trail.

  2016cites this paper
• Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

  2016cites this paper
• To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients

  2016cites this paper
• Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer

  2016cites this paper
• Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

  2016influential citation
• A Physical Mechanism and Global Quantification of Breast Cancer

  2016cites this paper
• Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

  2016influential citation
• Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context

  2016cites this paper
• Gene Expression Models of Signaling Pathways

  2016cites this paper
• Modulation of antitumor immunity by the MEK inhibitor trametinib: Implications for targeted therapy of cancer

  2016cites this paper
• The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers.

  2016cites this paper
• Allosteric MEK1/2 Inhibitors for the Treatment of Cancer: an Overview

  2015cites this paper
• Abstract 4842: Pharmacodynamic stratification of metastatic colorectal cancer patients using genomic datasets

  2015cites this paper
• Whole transcriptome analysis reveals an 8-oxoguanine DNA glycosylase-1-driven DNA repair-dependent gene expression linked to essential biological processes.

  2015influential citation
• The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

  2015cites this paper
• The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma

  2015influential citation
• MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

  2015cites this paper
• MiR‐96‐5p influences cellular growth and is associated with poor survival in colorectal cancer patients

  2015cites this paper
• A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies

  2015influential citation
• Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

  2015cites this paper
• Gene expression profiling for targeted cancer treatment

  2015cites this paper
• A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

  2015cites this paper
• Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung

  2015influential citation
• Treatment Strategies for KRAS Mutated Non-small Cell Lung Cancer

  2015cites this paper
• MicroRNAs and Regulatory Pathways in Tumorigenesis

  2014cites this paper
• Identifying Novel Targetable Genes and Pathways in Cancer by Integrating Diverse Omics Data.

  2014cites this paper